{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:47Z","timestamp":1789430447776,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.vaccine.2018.09.023","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T15:14:28Z","timestamp":1537542868000},"page":"6782-6789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial"],"prefix":"10.1016","volume":"36","author":[{"given":"Kai","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jielai","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuemei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2018.09.023_b0005","first-page":"595","article-title":"Medicine and the media: polio still paralyses (Albert Sabin, Jonas Salk)","volume":"18","author":"Dixon","year":"1977","journal-title":"Brit J Hosp Med"},{"issue":"48","key":"10.1016\/j.vaccine.2018.09.023_b0010","first-page":"219","article-title":"Global eradication of poliomyelitis by the year 2000","volume":"63","author":"Anon","year":"1988","journal-title":"Can Dis Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.09.023_b0015","first-page":"201","article-title":"Meeting of the strategic advisory group of experts on immunization, november 2012-conclusions and recommendations","volume":"21","author":"World Health Organization","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2018.09.023_b0020","unstructured":"World Health Organization. South-east Asia region declared polio-free; 2014 <http:\/\/polioeradication.org\/news-post\/who-south-east-asia-region-declared-polio-free\/>."},{"key":"10.1016\/j.vaccine.2018.09.023_b0025","first-page":"153","article-title":"Tracking progress towards global polio eradication, 2011\u20132012","volume":"15","author":"World Health Organization","year":"2013","journal-title":"Wkly Epidemiol Rec"},{"issue":"12","key":"10.1016\/j.vaccine.2018.09.023_b0030","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1099\/0022-1317-73-12-3065","article-title":"The molecular biology of poliovaccines","volume":"73","author":"Minor","year":"1992","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.09.023_b0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.biologicals.2006.02.007","article-title":"Vaccine-derived polioviruses","volume":"34","author":"Agol","year":"2006","journal-title":"Biologicals"},{"issue":"1","key":"10.1016\/j.vaccine.2018.09.023_b0040","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.vaccine.2018.09.023_b0045","first-page":"436","article-title":"Current situation of research on vaccine-associated paralytic poliomyelitis of oral polio vaccine [in Chinese]","volume":"123","author":"Zhou","year":"2007","journal-title":"J Prev Med Inf"},{"key":"10.1016\/j.vaccine.2018.09.023_b0050","unstructured":"World Health Organization. Polio eradication and endgame strategic plan 2013\u20132018; 2012 <http:\/\/polioeradication.org\/who-we-are\/strategy\/>."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.09.023_b0055","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1093\/infdis\/jiu184","article-title":"Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden","volume":"210","author":"Platt","year":"2014","journal-title":"J Infect Dis"},{"issue":"Suppl 1(19)","key":"10.1016\/j.vaccine.2018.09.023_b0060","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1093\/infdis\/jiu295","article-title":"Vaccine-derived polioviruses","volume":"210","author":"Burns","year":"2014","journal-title":"J Infect Dis"},{"issue":"35","key":"10.1016\/j.vaccine.2018.09.023_b0065","first-page":"934","article-title":"Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine-worldwide, 2016","volume":"65","author":"Hampton","year":"2016","journal-title":"MMWR"},{"issue":"22","key":"10.1016\/j.vaccine.2018.09.023_b0070","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1016\/j.vaccine.2010.02.095","article-title":"The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox","volume":"28","author":"Heinsbroek","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.09.023_b0075","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4155\/ppa.12.70","article-title":"Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains","volume":"1","author":"Hamidi","year":"2012","journal-title":"Pharm Pat Anal"},{"key":"10.1016\/j.vaccine.2018.09.023_b0080","unstructured":"World Health Organization. Polio vaccines: WHO position paper; 2016 [25 March 2016] <http:\/\/www.who.int\/immunization\/policy\/position_papers\/polio\/en\/>."},{"issue":"2","key":"10.1016\/j.vaccine.2018.09.023_b0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.biologicals.2006.02.011","article-title":"Technology transfer of Sabin-IPV to new developing country markets","volume":"34","author":"Kreeftenberg","year":"2006","journal-title":"Biologicals"},{"issue":"41","key":"10.1016\/j.vaccine.2018.09.023_b0090","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.023_b0095","unstructured":"WHO Expanded Programme on Immunization, World Health Organization. Manual for the virological investigation of poliomyelitis; 1990 <http:\/\/apps.who.int\/iris\/handle\/10665\/62186?locale=ar>."},{"key":"10.1016\/j.vaccine.2018.09.023_b0100","unstructured":"China Food and Drug Administration (CFDA). The guidance principle of grade standard for adverse reactions that occur in clinical trial of preventive vaccines. Beijing: CFDA; 2005 <http:\/\/samr.cfda.gov.cn\/WS01\/CL1616\/83435.html>."},{"issue":"2","key":"10.1016\/j.vaccine.2018.09.023_b0105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir723","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial","volume":"205","author":"Liao","year":"2012","journal-title":"J Infec Dis"},{"key":"10.1016\/j.vaccine.2018.09.023_b0110","unstructured":"National Health Commission of the people\u2019s republic of China. Child immunization schedule and instructions of national immunization program vaccine; 2016 <http:\/\/www.nhfpc.gov.cn>."},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2018.09.023_b0115","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1086\/322575","article-title":"Combination vaccines: choices or chaos? A practitioner's perspective","volume":"33","author":"Le","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.09.023_b0120","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1086\/314901","article-title":"The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination","volume":"180","author":"Goldblatt","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.023_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2018.1489188","article-title":"Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: a systematic review and meta-analysis","volume":"11","author":"Tang","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2018.09.023_b0130","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1080\/21645515.2017.1288769","article-title":"Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non-inferiority clinical trial","volume":"13","author":"Qiu","year":"2017","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18312726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18312726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T15:55:40Z","timestamp":1544457340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18312726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":26,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0264410X18312726"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}